Gsa Capital Partners LLP Enanta Pharmaceuticals Inc Transaction History

Gsa Capital Partners LLP

$1.32 Billion
Q3 2024

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 16, 2024	BUY	$8.18 - $10.78 $46,724 - $61,575	5,712 Added 24.77%	28,770 $270,000
Q3 2023 Nov 15, 2023	SELL	$11.09 - $22.13 $98,856 - $197,266	-8,914 Reduced 27.88%	23,058 $257,000
Q2 2023 Aug 14, 2023	SELL	$20.68 - $39.85 $134,854 - $259,861	-6,521 Reduced 16.94%	31,972 $684,000
Q1 2023 May 12, 2023	BUY	$38.82 - $54.59 $1.07 Million - $1.5 Million	27,436 Added 248.13%	38,493 $1.56 Million
Q4 2022 Feb 13, 2023	BUY	$40.77 - $53.73 $450,793 - $594,092	11,057 New	11,057 $514,000
Q3 2021 Nov 12, 2021	SELL	$41.02 - $58.65 $257,646 - $368,380	-6,281 Closed	0 $0
Q2 2021 Aug 05, 2021	BUY	$43.76 - $53.11 $274,856 - $333,583	6,281 New	6,281 $276,000
Q4 2020 Feb 03, 2021	SELL	$41.16 - $47.47 $441,029 - $508,641	-10,715 Closed	0 $0
Q3 2020 Nov 06, 2020	BUY	$43.36 - $53.53 $285,438 - $352,387	6,583 Added 159.32%	10,715 $491,000
Q2 2020 Aug 11, 2020	BUY	$46.37 - $57.58 $191,600 - $237,920	4,132 New	4,132 $207,000
Q1 2020 May 12, 2020	SELL	$40.22 - $62.0 $596,422 - $919,398	-14,829 Closed	0 $0
Q4 2019 Feb 12, 2020	BUY	$57.95 - $66.61 $582,397 - $669,430	10,050 Added 210.3%	14,829 $916,000
Q3 2019 Nov 12, 2019	SELL	$60.08 - $88.17 $443,450 - $650,782	-7,381 Reduced 60.7%	4,779 $287,000
Q2 2019 Aug 06, 2019	SELL	$81.3 - $97.35 $263,412 - $315,414	-3,240 Reduced 21.04%	12,160 $1.03 Million
Q1 2019 May 15, 2019	BUY	$69.08 - $105.66 $207,240 - $316,980	3,000 Added 24.19%	15,400 $1.47 Million
Q4 2018 Feb 12, 2019	SELL	$65.41 - $84.65 $183,148 - $237,020	-2,800 Reduced 18.42%	12,400 $878,000
Q3 2018 Nov 13, 2018	SELL	$85.46 - $126.37 $786,232 - $1.16 Million	-9,200 Reduced 37.7%	15,200 $1.3 Million
Q2 2018 Aug 09, 2018	BUY	$81.85 - $120.51 $1.52 Million - $2.24 Million	18,600 Added 320.69%	24,400 $2.83 Million
Q1 2018 May 11, 2018	SELL	$57.91 - $92.15 $208,476 - $331,740	-3,600 Reduced 38.3%	5,800 $469,000
Q4 2017 Feb 14, 2018	SELL	$45.65 - $59.37 $470,195 - $611,511	-10,300 Reduced 52.28%	9,400 $552,000
Q3 2017 Nov 20, 2017	BUY	$37.91 - $46.8 $746,826 - $921,960	19,700	19,700 $922,000

Others Institutions Holding ENTA

# of Institutions

110

Shares Held

21.1M

Call Options Held

4.8K

Put Options Held

4.6K

Farallon Capital Management LLC San Francisco, CA

2.11M
Shares

$19.7 Million
0.11% of portfolio
Vanguard Group Inc Valley Forge, PA

1.98M
Shares

$18.5 Million
0.0% of portfolio
Black Rock Inc. New York, NY

1.85M
Shares

$17.3 Million
0.0% of portfolio
Krensavage Asset Management, LLC New York, NY

1.5M
Shares

$14 Million
8.7% of portfolio
Morgan Stanley New York, NY

1.1M
Shares

$10.3 Million
0.0% of portfolio

View Full List

About ENANTA PHARMACEUTICALS INC

Ticker ENTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 20,724,900
Market Cap $194M
Description
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and li...

More about ENTA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

News

Stay updated on Gsa Capital Partners LLP with notifications on news.

Account